Actively Recruiting
Safety Comparison of Aspirin and Warfarin for Six Months After Bioprosthetic Heart Valve Replacement
Led by Asan Medical Center · Updated on 2026-07-06
1058
Participants Needed
3
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial evaluates the safety of two oral antithrombotic therapies, aspirin and vitamin K antagonists warfarin, during the first six months after bioprosthetic heart valve replacement in the aortic or mitral positions. It is a multinational, multicenter, randomized, open-label, active-controlled study designed to compare these treatments in patients who have undergone tissue valve replacement surgery. Participants are randomly assigned to receive either aspirin at a dose of 100 mg once daily for six months or warfarin with a target International Normalized Ratio INR maintained between 2.0 and 3.0 for six months. The study focuses on the initial six-month period following valve replacement surgery to monitor treatment effects. Throughout the six months, participants will be monitored for a composite of clinical events including stroke, transient ischemic attack, systemic embolism, myocardial infarction, major bleeding, valve thrombosis, and all-cause mortality. These outcomes will be assessed to evaluate safety. Participants will follow a clinical schedule with regular follow-up visits as part of the study protocol.
CONDITIONS
Brief Title
Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprosthetic Heart Valve Replacement
Research Team
J
Joon-bum Kim, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here